Angiogenesis extent and expression of matrix metalloproteinase-2 and-9 agree with progression of ovarian endometriomas

被引:81
作者
Ria, R
Loverro, G
Vacca, A
Ribatti, D
Cormio, G
Roccaro, AM
Selvaggi, L
机构
[1] Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy
[2] Univ Bari, Sch Med, Dept Obstet & Gynaecol, I-70124 Bari, Italy
[3] Univ Bari, Sch Med, Dept Human Anat & Histol, I-70124 Bari, Italy
关键词
angiogenesis; chorioallantoic membrane; metalloproteinases; ovarian endometrioma;
D O I
10.1046/j.1365-2362.2002.00960.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Changes in angiogenesis and expression of extracellular matrix-degrading enzymes have been substantiated in turnout changeover and progression. Methods Tissues from 44 biopsies of stage III and IV ovarian endometriomas, and 10 biopsies of normal (control) endometrium were investigated immunohistochemically to count microvessels, and by in situ hybridization to assess the expression of mRNA of matrix metalloproteinase-2 (MMP-2) and MMP-9. Implants of the tissues were investigated in the chick embryo chorioallantoic membrane (CAM) assay to determine their angiogenic capacity. Results The endometriomas displayed significantly higher counts than normal endometria and the highest values were associated with the deepest invasion level (stage IV). Microvessels localized in close association with ectopic endometrial cells in the form of winding and arborized tubes, often dilated in microaneurysmatic segments. These were absent in normal endometrium. Expression of MMP-2 and MMP-9 mRNA, evaluated as percentages of positive biopsies and intensity of expression, was up-regulated in endometriomas and more pronounced in stage IV. MMP-2 and MMP-9 mRNA were also expressed by host stromal cells, including microvascular endothelial cells, fibroblasts and macrophages, whereas the control endometrium showed very little expression of MMP-2 mRNA in a few endothelial cells and no expression of MMP-9 mRNA. Implants from stage IV endometrioma induced a more intense vasoproliferative response than those from stage III, while no vasoproliferative response was induced by the normal endometrium. Conclusion These data suggest that angiogenesis and degradation of extracellular matrix occur together in endometriosis and are more pronounced in stage IV, and that endometriosis cells and some host stromal cell populations co-operate in disease progression.
引用
收藏
页码:199 / 206
页数:8
相关论文
共 45 条
[1]  
*AM FERT SOC, 1985, FERTIL STERIL, V43, P351
[2]   Endometriosis - A disease because it is characterized by bleeding [J].
Brosens, IA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 176 (02) :263-267
[3]   Progesterone and transforming growth factor-β coordinately regulate suppression of endometrial matrix metalloproteinases in a model of experimental endometriosis [J].
Bruner, KL ;
Etsenberg, E ;
Gorstein, F ;
Osteen, KG .
STEROIDS, 1999, 64 (09) :648-653
[4]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[5]  
Elias H, 1983, GUIDE PRACTICAL STER, P25
[6]   High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata [J].
Fasciani, A ;
D'Ambrogio, G ;
Bocci, G ;
Monti, M ;
Genazzani, AR ;
Artini, PG .
MOLECULAR HUMAN REPRODUCTION, 2000, 6 (01) :50-54
[7]   Expression of platelet-derived endothelial cell growth factor and its mRNA in uterine endometrium during the menstrual cycle [J].
Fujimoto, J ;
Ichigo, S ;
Sakaguchi, H ;
Hirose, R ;
Tamaya, T .
MOLECULAR HUMAN REPRODUCTION, 1998, 4 (05) :509-513
[8]   Angiogenesis in endometriosis and angiogenic factors [J].
Fujimoto, J ;
Sakaguchi, H ;
Hirose, R ;
Wen, HW ;
Tamaya, T .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1999, 48 :14-18
[9]  
Gottschalk C, 2000, ADV EXP MED BIOL, V477, P483
[10]   TISSUE INHIBITORS OF METALLOPROTEINASES IN ENDOMETRIUM OF OVARIECTOMIZED STEROID-TREATED EWES AND DURING THE ESTROUS-CYCLE AND EARLY-PREGNANCY [J].
HAMPTON, AL ;
BUTT, AR ;
RILEY, SC ;
SALAMONSEN, LA .
BIOLOGY OF REPRODUCTION, 1995, 53 (02) :302-311